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S U M M A R Y
Background: The mortality rate of patients with Clostridium perfringens bacteremia is 27–44%. Typically,
the clinical characteristics of this infection are non-speciﬁc, which leads to considerable difﬁculty with
the diagnosis and early initiation of appropriate therapy.
Methods: A retrospective cohort study of patients who were hospitalized between August 2002 and July
2011 with C. perfringens bacteremia was conducted within a 3715-bed teaching hospital in northern
Taiwan. The patients identiﬁed in this search were included when they had fever or other clinical
features suggestive of systemic infection. Multiple logistic regression analysis was applied to determine
the independent risk factors of 30-day mortality.
Results: A total of 93 patients were identiﬁed. Elderly patients with comorbid illnesses, especially renal
insufﬁciency or malignancy, were at risk of developing C. perfringens bacteremia, and 23 patients (24.7%)
had nosocomial bacteremia. The 30-day and attributed mortalities were 26.9% (25/93) and 8.6% (8/93),
respectively. Nosocomial infection was a signiﬁcant predictor for mortality within 30 days (odds ratio
19.378, 95% conﬁdence interval 2.12–176.99; p = 0.009), independent of other disease parameters. Other
independent risk factors included the Charlson weighted index of comorbidity, length of hospitalization,
and stay in the intensive care unit.
Conclusions: Early recognition of this critical infection and early initiation of appropriate antibiotic
treatment by surgical intervention or drainage is essential.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Clostridium species are Gram-positive, spore-forming, obligate
anaerobic bacilli. Generally, many of them are considered
saprophytic, and some are pathogenic to humans and animals.1,2
Clostridia are ubiquitous and found in soil, decaying vegetation,
marine sediment, and the intestinal tract of humans. Clostridium
perfringens, the most frequent clinical isolate of Clostridium, is
often encapsulated, non-motile, and rarely sporulated in artiﬁcial
media. C. perfringens strains are classiﬁed into ﬁve types, A through
E, according to lethal toxin production. C. perfringens patients
exhibit various clinical symptoms, including infections of skin and
soft tissue,3 gastroenteritis,4 gas gangrene,5 necrotizing enteritis,4
liver abscess,6 endophthalmitis,7 bacteremia, and septic shock
with acute hemolysis.5,8–12
The 30-day mortality rate of patients with C. perfringens
bacteremia is 27–44%,5,13–16 and most infections have exhibited no
speciﬁc clinical characteristics except for minimal systemic* Corresponding author. Tel.: +886 3 328 1200 ext. 8450; fax: +886 3 328 9410.
E-mail address: drharrylee@gmail.com (M.-H. Lee).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.03.001inﬂammatory syndromes. This ﬁnding indicates that an early
diagnosis and initiation of appropriate treatment for C. perfringens
bacteremia may be very difﬁcult. Because a limited number of
studies have investigated the clinical characteristics and risk
factors for mortality among patients with C. perfringens bacter-
emia, we conducted a retrospective cohort study in a large tertiary
care hospital. Our aims were to: (1) describe the characteristics of
clinically signiﬁcant C. perfringens bacteremia cases in a large
tertiary care hospital over a 10-year period; (2) deﬁne the risk
factors of fatal C. perfringens bacteremia relative to non-fatal cases;
and (3) determine the differences between community-acquired
and nosocomial C. perfringens bacteremia.
2. Methods
2.1. Study design and setting
This retrospective cohort study was conducted at the Chang
Gung Memorial Hospital at Linkou (CGMH-Linkou), a 3715-bed
university-afﬁliated academic tertiary care medical center in
northern Taiwan. The study was approved by the institutional
review board of the CGMH-Linkou (Number 100-2949B).ses. Published by Elsevier Ltd. All rights reserved.
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All inpatients with an episode of C. perfringens bacteremia
occurring between August 2002 and July 2011 were identiﬁed
through the Clinical Microbiology Laboratory, which processes all
clinical specimens. A case was considered when a patient had at
least one blood culture positive for C. perfringens during the period
of microbial isolation and exhibited clinical features suggestive of a
systemic infection. For patients with multiple episodes of C.
perfringens bacteremia, only the ﬁrst episode was included in the
analysis.
2.3. Microbiological identiﬁcation and susceptibility testing of C.
perfringens isolates
Identiﬁcation and susceptibility testing of C. perfringens were
performed and interpreted according to standard methods.17,18 In
addition, culture on kanamycin–vancomycin–colistin–laked blood
agar (LBA) plates (BD Microbiology Systems, Cockeysville, MD,
USA)19 was used to differentiate isolates. Antimicrobial suscepti-
bility testing was performed by the agar dilution method described
by the Clinical and Laboratory Standards Institute, with the use of
Brucella–LBA containing hemin and vitamin K1 (BD Microbiology
Systems, Cockeysville, MD, USA).19 The tested antibiotics in the
panel were penicillin, clindamycin, piperacillin, metronidazole,
and ampicillin/sulbactam.
2.4. Data collection
Patient medical records were used as the source of data for
demographics, comorbid illnesses, coexisting bloodstream patho-
gens, clinical features, Charlson weighted index of comorbidity
(WIC),20 Pitt bacteremia score,21 laboratory and imaging ﬁndings,
sources of bacteremia, length of hospitalization, stay in intensive
care unit (ICU), outcomes, and susceptibility tests on blood
isolates. The comorbid illnesses that we identiﬁed in our patients
included renal insufﬁciency (deﬁned as serum creatinine 1.4 mg/
dl, or the requirement for hemodialysis), malignancy, diabetes
mellitus, hypertension, liver cirrhosis, cerebral vascular accident,
heart failure, gall stones, bowel obstruction, use of immunosup-
pressants (deﬁned as the use of prednisone during hospitalization
(20 mg per day or equivalent for at least 2 weeks, or 100 mg per day
for at least 3 days), or chemotherapy for cancer patients within 14
days of bacteremia onset), and recent surgery (surgical procedures
performed 3 months or less before the onset of infection).
Community-acquired bacteremia was deﬁned as a positive
blood culture taken within 48 h of admission or true community
onset. Nosocomial bacteremia was deﬁned as a positive blood
culture obtained more than 48 h after admission. Polymicrobial
bacteremia was deﬁned as one or more additional bacterial species
isolated from blood concurrently with C. perfringens. The Pitt
bacteremia score was calculated to assess the severity. Scoring was
based on the following criteria: (1) ear temperature, 2 points for
<35 8C or 40 8C, 1 point for 35.1–36.0 8C or 39.0–39.9 8C, and 0
points for 36.1–38.9 8C; (2) hypotension, 2 points for acute
hypotensive event with >30 mmHg decrease in systolic blood
pressure and >20 mmHg decrease in diastolic pressure, the use of
intravenous vasopressor agents, or a systolic pressure <90 mmHg;
(3) the need for mechanical ventilation, 2 points; (4) cardiac arrest,
4 points; and (5) mental status, 0 points if alert, 1 point if
disoriented, 2 points if stuporous, and 4 points if comatose.
The Charlson WIC was determined by the sum of the following
assigned scores for each condition: 1 for myocardial infarct,
congestive heart failure, peripheral vascular disease, cerebrovas-
cular disease, dementia, chronic pulmonary disease, connective
tissue disease, ulcer disease, mild liver disease, or diabetes; 2 forhemiplegia, moderate or severe renal disease, diabetes with end-
organ damage, tumors (any), leukemia, or lymphoma; 3 for
moderate or severe liver disease; and 6 for metastatic solid tumors
and AIDS.
Leukocytosis was deﬁned as leukocytes >10  109 cells/l and
leukopenia as leukocytes <4  109 cells/l. Neutropenia was
deﬁned as absolute neutrophils <0.5  109 cells/l. Anemia was
deﬁned as hemoglobin <13 g/dl in men and <12 g/dl in women.
Thrombocytopenia was deﬁned as platelets <150  109 cells/l.
Hepatic dysfunction was deﬁned as the occurrence of two or more
of the following: bilirubin concentration >2.5 mg/dl, aspartate
aminotransferase or alanine aminotransferase 2 times the upper
normal limit, and known severe liver disease. Fever was deﬁned as
any body temperature 38 8C, and hypothermia was deﬁned as
any body temperature <36 8C.
Sources of bacteremia were determined from the medical
records, imaging studies, surgical ﬁndings, and microbiological
evidence, not only by the physician in charge, but also by the
review of an infection specialist. Bacteremia sources were
classiﬁed as intra-abdominal sites, lower or upper respiratory
tract, skin, bone and soft tissue, urinary tract, and primary without
any deﬁnite focus. Adequate antimicrobial treatment was deﬁned
as antibiotics effective against C. perfringens in vitro being
administered within 48 h of bacteremia onset, subsequent to
the receipt of ﬁnal blood culture results, and continuously for at
least 3 days. Adjunctive therapy was deﬁned as concurrent to
surgical intervention or palliative drainage.
The 30-day mortality, deﬁned as the mortality within 30 days of
bacteremia onset, was recorded. Bacteremia-attributed mortality
was considered if mortality occurred within 7 days of C. perfringens
bacteremia onset, with profound shock, multiple organ failure, and
no other identiﬁed cause of death.
2.5. Statistical analysis
Categorical variables were compared using the Chi-square test
or Fisher’s exact test as appropriate. Continuous variables were
tested for normality of distributions by the Kolmogorov–Smirnov
test and compared by the Student’s t-test or Mann–Whitney U-test
as appropriate. The odds ratio (OR) and 95% conﬁdence interval (CI)
were calculated as well. In the univariate analysis, variables with a
two-tailed p < 0.05 were included in a multiple logistic regression
to determine independent risk factors for 30-day mortality. All
tests were two-tailed, and p < 0.05 was considered signiﬁcant in
the multivariate analysis. All statistical calculations were per-
formed with standard programs of the Statistical Package for the
Social Sciences for Windows, version 18.0 (PASW, Chicago, IL, USA).
3. Results
3.1. Demographics, comorbidities, and microbiological characteristics
Based on inclusion of the ﬁrst episode of bacteremia only, 132
patients with C. perfringens bacteremia were identiﬁed; the overall
annual incidence was 0.97 per 100 000 population during the study
period. Of these, 39 were excluded from the study for incomplete
treatment course (two patients), lack of complete medical records
(two patients), and lack of correlated clinical features suggestive of
systemic infection (35 patients). Finally, 93 patients were included
in the analysis. After exclusion of four patients’ isolates that lacked
adequate clinical information, 72.7% (93/128) of the clinical blood
isolates were clinically signiﬁcant. The corresponding demographics
and clinical features are summarized in Table 1. The mean age of the
patients was 70.7 years (range 38–94 years) and males were
predominant (54/93 patients, 58.1%). The most common comorbid-
ities were renal insufﬁciency (49.5%), malignancy (41.9%), and
Table 1




Male gender 54 (58.1%)
Age, years 70.7  13.1
Comorbidities
Renal insufﬁciency 46 (49.5%)
Malignancy 39 (41.9%)
Hypertension 24 (25.8%)
Diabetes mellitus 21 (22.6%)
Liver cirrhosis 16 (17.2%)
Cerebral vascular accident 11 (11.8%)
Heart failure 10 (10.8%)
Use of immunosuppressants 10 (10.8%)
Gall stones 6 (6.5%)
Bowel obstruction 2 (2.2%)
Recent admission 19 (20.4%)
Recent surgery 11 (11.8%)
Initial presentations
Nosocomial infection 23 (24.7%)
Polymicrobial bacteremia 51 (54.8%)
Pitt bacteremia score 2.4  2.98






Liver dysfunction 39 (41.9%)
Fever 54 (58.1%)
Abdominal pain 42 (45.2%)
Change of consciousness 15 (16.1%)
Shock at presentation 11 (11.8%)
Weakness 7 (7.5%)
Hypothermia 7 (7.5%)
Gas formation 6 (6.5%)
Sources of bacteremia
Intra-abdominalb 49 (52.7%)
Unknown primary 23 (24.7%)
Lower respiratory tract 18 (19.4%)
Upper respiratory tract 1 (1.1%)
Skin, soft tissue, and bone 1 (1.1%)
Urinary tract 1 (1.1%)
Therapy and outcomes
Adequate antimicrobial treatment 59 (63.4%)
Surgical treatment 14 (15.1%)
Drainage or aspiration 16 (17.2%)
Stay in ICU 31 (33.3%)
Length of hospital stay, days 23.3  22.8
30-day mortality 25 (26.9%)







WIC, weighted index of comorbidity; ICU, intensive care unit.
a Results are n (%), or mean  standard deviation.
b Eleven patients had peritonitis, 11 had cholangitis, eight had
cholecystitis, seven had liver abscess, four had hollow organ perforation,
three had pancreatitis, three had diverticulitis, and one had intra-
abdominal abscess and colitis.
c Data are antibiotic susceptibility rates of blood isolates of C.
perfringens from each group, presented as number of isolates (suscepti-
bility rate %).
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testinal (GI) malignancy was the most common (n = 26 patients),
followed by urogenital (n = 5), lung (n = 3), sarcoma (n = 2),
leukemia (n = 2), and unknown malignancies (n = 1). Of the 26 GI
malignancies, hepatocellular carcinoma was the most common
(n = 13 patients), followed by cholangiocarcinoma (n = 5), colorectal
(n = 4), gastric (n = 2), and pancreatic cancers (n = 2).3.2. Initial presentation
Twenty-three patients (24.7%) had nosocomial bacteremia.
Fifty-one patients (54.8%) had polymicrobial bacteremia with the
following organisms isolated from concurrent blood cultures:
Escherichia coli (n = 21 patients), Klebsiella pneumoniae (n = 11),
coagulase-negative staphylococci (n = 8), anaerobic ﬂora (n = 5),
and others (n = 19).
The mean Pitt bacteremia and Charlson WIC scores were 2.4
and 3.6, respectively. Most patients presented initially with
systemic inﬂammation such as fever, leukocytosis, anemia, and
thrombocytopenia. Abdominal pain was noted most often (42
patients, 45.2%), followed by change of consciousness and shock.
3.3. Sources of bacteremia, therapy, and outcomes
Intra-abdominal infection (IAI) was the most common source of
bacteremia (49/93, 52.7%), and most patients in this group
underwent either surgical intervention (12/49, 24.5%) or palliative
drainage (14/49, 28.6%) during the treatment period. Of the IAI
patients, 32 (65.3%) had polymicrobial bacteremia and their 30-
day mortality was 22.4% (11/49). The most common comorbidities
were malignancy (22/49, 44.9%), liver cirrhosis (12/49, 24.5%), and
gall stones (6/49, 12.2%).
Twenty-three patients (24.7%) had primary C. perfringens
bacteremia. Of these, 10 had malignancies, including hepatocellu-
lar carcinoma (n = 4) and other GI sites (n = 4). Six patients (26.1%)
died in this group.
The third most common identiﬁed source was the lower
respiratory tract. Eighteen patients (19.3%) had lower respiratory
tract infections (pneumonia, n = 17; empyema, n = 1) with a high
rate of respiratory failure (10/18, 55.6%) and 30-day mortality (8/
18, 44.4%).
Of the 93 studied patients, 59 (63.4%) received adequate
antimicrobial treatment and 30 (32.3%) had adjunctive surgery
or drainage. Among the patients with adequate antimicrobial
treatment, imipenem/cilastatin was used for four cases, ﬂo-
moxef for one, piperacillin/tazobactam for one, clindamycin for
one, a combination of two or more antibiotics containing
metronidazole for 38, a combination containing clindamycin for
nine, and a combination containing penicillin derivatives for
ﬁve. The mean length of hospitalization was 23.3 days. The 30-
day and attributed mortalities were 26.9% (25/93) and 8.6% (8/
93), respectively.
3.4. Antimicrobial susceptibility testing
Most C. perfringens blood isolates were susceptible to the
antibiotics tested (Table 1); resistance was observed in only seven
isolates, primarily to penicillin (n = 4 patients) and clindamycin
(n = 3). Of the seven drug-resistant isolates, ﬁve (71.4%) were
community-acquired.
3.5. Risk factors for 30-day mortality
The univariate analysis of the risk factors for 30-day mortality is
shown in Table 2. There were no signiﬁcant differences in
demographics, comorbidities, polymicrobial bacteremia, sources
of bacteremia, and therapies between those who survived and
those who died. Compared to the patients who survived, those who
died had a higher rate of nosocomial infections (56.0% vs. 13.2%,
p < 0.001), anemia (80.0% vs. 54.4%, p = 0.025), and shock at
presentation (28.0% vs. 11.8%, p = 0.003). The deceased also had
higher Pitt bacteremia scores (4.4  3.91 vs. 1.6  2.13, p = 0.009)
and Charlson WIC (5.0  2.41 vs. 3.0  2.53, p = 0.001) than those
who survived. In addition, those who survived had a higher rate of
Table 2





OR (95% CI) p-Value
Demographics
Male gender 40 (58.8%) 14 (56.0%) 0.891 (0.353–2.248) 0.807
Age, years 71.1  13.47 69.5  12.30 0.607
Comorbidities
Renal insufﬁciency 30 (44.1%) 16 (64.0%) 2.252 (0.874–5.803) 0.089
Malignancy 25 (36.8%) 14 (56.0%) 2.189 (0.863–5.553) 0.096
Hypertension 17 (25.0%) 7 (28.0%) 1.167 (0.416–3.272) 0.769
Diabetes mellitus 13 (19.1%) 8 (32.0%) 1.991 (0.707–5.605) 0.188
Liver cirrhosis 10 (14.7%) 6 (24.0%) 1.832 (0.588–5.710) 0.355
Cerebral vascular accident 9 (13.2%) 2 (8.0%) 0.570 (0.114–2.841) 0.721
Heart failure 7 (10.3%) 3 (12.0%) 1.188 (0.282–5.004) 0.814
Use of immunosuppressants 5 (7.4%) 5 (20.0%) 3.150 (0.827–12.003) 0.126
Gall stones 6 (8.8%) 0 (0) N/A 0.186
Bowel obstruction 2 (2.9%) 0 (0) N/A 1
Recent admission 11 (16.2%) 8 (32.0%) 2.439 (0.845–7.036) 0.093
Recent surgery 6 (8.8%) 5 (20.0%) 2.583 (0.712–9.379) 0.139
Initial presentations
Nosocomial infection 9 (13.2%) 14 (56.0%) 8.343 (2.902–23.991) <0.001
Polymicrobial bacteremia 39 (57.4%) 12 (48.0%) 0.686 (0.274–1.723) 0.422
Pitt bacteremia score 1.6  2.13 4.4  3.91 0.009
Charlson WIC 3.0  2.53 5.0  2.41 0.001
Leukocytosis 38 (55.9%) 14 (56.0%) 1.005 (0.399–2.530) 0.992
Leukopenia 5 (7.4%) 5 (20.0%) 3.150 (0.827–12.003) 0.081
Neutropenia 1 (1.5%) 2 (8.0%) 5.826 (0.504–67.295) 0.114
Anemia 37 (54.4%) 20 (80.0%) 3.35 (1.127–9.968) 0.025
Thrombocytopenia 25 (36.8%) 13 (52.0%) 1.863 (0.738–4.707) 0.185
Abnormal liver function 35 (51.5%) 15 (60.0%) 1.414 (0.558–3.587) 0.465
Liver dysfunction 27 (39.7%) 12 (48.0%) 1.402 (0.557–3.527) 0.472
Fever 36 (52.9%) 16 (64.0%) 1.580 (0.614–4.067) 0.341
Abdominal pain 36 (52.9%) 6 (24.0%) 0.281 (0.100–0.789) 0.013
Change of consciousness 8 (11.8%) 7 (28.0%) 2.917 (0.930–9.147) 0.059
Shock at presentation 4 (5.9%) 7 (28.0%) 6.222 (1.637–23.648) 0.003
Weakness 4 (5.9%) 3 (12.0%) 2.182 (0.452–10.523) 0.381
Hypothermia 3 (4.4%) 4 (16.0%) 4.127 (0.854–19.951) 0.081
Gas formation 3 (4.4%) 3 (12.0%) 2.955 (0.555–15.722) 0.338
Source of bacteremia
Intra-abdominal 38 (55.9%) 11 (44.0%) 0.620 (0.246–1.562) 0.39
Unknown primary 17 (25.0%) 6 (24.0%) 0.947 (0.325–2.760) 0.921
Lower respiratory tract 10 (14.7%) 8 (32.0) 2.729 (0.931–8.001) 0.061
Upper respiratory tract 1 (1.5%) 0 (0) N/A 1
Skin, soft tissue, and bone 1 (1.5%) 0 (0) N/A 1
Urinary tract 1 (1.5%) 0 (0) N/A 1
Therapy
Adequate antibiotic use 44 (64.7%) 15 (60.0%) 0.818 (0.319–2.099) 0.676
Adjunctive therapy 23 (33.8%) 7 (28.0%) 0.761 (0.278–2.083) 0.594
Stay in ICU 19 (27.9%) 12 (48.0%) 2.381 (0.924–6.135) 0.069
Length of hospital stay, days 25.6  25.27 17.0  12.18 0.03
OR, odds ratio; CI, conﬁdence interval; N/A, not available; WIC, weighted index of comorbidity; ICU, intensive care unit.
a Results are n (%), or mean  standard deviation.
Table 3
Multivariate analysis of the risk factors for 30-day mortalitya
Variable OR (95% CI) p-Value
Nosocomial infection 19.378 (2.12–176.99) 0.009
Length of hospital stay 0.904 (0.83–0.98) 0.018
Charlson WIC 1.666 (1.06–2.62) 0.027
ICU stay 9.923 (1.06–92.70) 0.044
OR, odds ratio; CI, conﬁdence interval; WIC, weighted index of comorbidity; ICU,
intensive care unit.
a All variables included in the ﬁnal multivariable model are displayed above.
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(25.6  25.27 vs. 17.0  12.18, p = 0.030) than those who died.
All variables with p < 0.1 were included in the multivariate
analysis; the independent risk factors were as follows: nosocomial
infections (OR 19.378, 95% CI 2.12–176.99; p = 0.009), Charlson
WIC (OR 1.666, 95% CI 1.06–2.62; p = 0.027), length of hospitaliza-
tion (OR 0.904, 95% CI 0.83–0.98; p = 0.018), and stay in the ICU (OR
9.923, 95% CI 1.06–92.70; p = 0.044) (Table 3).
3.6. Univariate analysis of nosocomial and community-acquired C.
perfringens bacteremia
Of the 23 patients with nosocomial C. perfringens bacteremia
(Table 4), the mean hospital stay before the onset of bacteremia
was 19.4 days (range 2–50 days). No signiﬁcant differences existed
between the patients with nosocomial and community-acquired
bacteremia with regard to age, major comorbidities, therapy, and
length of hospitalization after bacteremia. Compared to patients
with community-acquired bacteremia, patients with nosocomialbacteremia had a signiﬁcantly higher rate of male gender (78.3% vs.
51.4%, p = 0.024), immunosuppressant use (26.1% vs. 5.7%,
p = 0.006), fever (78.3% vs. 51.4%, p = 0.020), leukocytosis (39.1%
vs. 61.4%, p = 0.060), and 30-day mortality (60.9% vs. 15.7%,
p = 0.020). Also, patients with nosocomial bacteremia had a lower
rate of abdominal pain than patients with community-acquired
bacteremia (17.4% vs. 54.3%, p = 0.002). Patients with nosocomial
bacteremia had higher Pitt bacteremia scores (3.5 vs. 2.0, p = 0.031)
Table 4





OR (95% CI) p-Value
Demographics
Male gender 18 (78.3%) 36 (51.4%) 3.40 (0.14–10.17) 0.024
Age, years 67.4  11.64 71.8  13.47 0.166
Comorbidities
Renal insufﬁciency 12 (52.2%) 34 (48.6%) 1.16 (0.45–2.97) 0.764
Malignancy 13 (56.5%) 26 (37.1%) 2.20 (0.85–5.73) 0.102
Use of immunosuppressants 6 (26.1) 4 (5.7) 5.82 (1.48–22.98) 0.006
Initial presentations
Pitt bacteremia score 3.5  3.41 2.0  2.75 0.031
Charlson WIC 4.8  2.31 3.1  2.60 0.007
Fever 18 (78.3%) 36 (51.4%) 3.40 (1.14–10.17) 0.02
Leukocytosis 9 (39.1%) 43 (61.4%) 0.40 (0.15–1.06) 0.06
Abdominal pain 4 (17.4%) 38 (54.3%) 0.18 (0.06–0.56) 0.002
Sources of bacteremia
Intra-abdominal 8 (34.8%) 41 (58.6%) 0.38 (0.14–1.01) 0.047
Unknown primary 9 (39.1%) 14 (20.0%) 2.57 (0.93–7.14) 0.065
Lower respiratory tract 6 (26.1%) 12 (17.1%) 1.71 (0.56–5.22) 0.370
Therapy
Adequate antibiotic use 11 (47.8%) 48 (68.6%) 0.42 (0.16–1.10) 0.073
Adjunctive therapy 4 (17.4%) 26 (37.1%) 0.36 (0.11–1.16) 0.079
Outcomes
30-day mortality 14 (60.9%) 11 (15.7%) 8.34 (2.90–23.99) <0.001
LOS after bacteremia, days 15.2  11.38 15.2  24.27 0.068
OR, odds ratio; CI, conﬁdence interval; WIC, weighted index of comorbidity; LOS, length of hospital stay.
a Only signiﬁcant (p < 0.05) and selected non-signiﬁcant variables are shown.
b Results are n (%), or mean  standard deviation.
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community-acquired bacteremia.
4. Discussion
To the best of our knowledge, this study represents the largest
assessment of the incidence, risk factors, and outcomes of patients
with C. perfringens bacteremia in a hospital-based population.
Several studies on clostridial infections have provided potentially
valuable insight and clinical experience, but they have not
distinguished the characteristic disease types caused by the
individual pathogen from other undeﬁned Clostridium spe-
cies.11,13,14,22 Those studies indicated that many clostridial blood
isolates may have no clinical signiﬁcance.16,23 Several recent
studies have demonstrated that Clostridium species are usually
pathogenic under certain conditions and that failure to institute
early, appropriate antimicrobial therapy may be associated with a
poor outcome.13,22,24 Our study used a strict deﬁnition for C.
perfringens bacteremia, and 72.7% of the clinical blood isolates
were clinically signiﬁcant. Physicians should be alert to elderly
patients with abdominal pain, septic symptoms, and polymicrobial
infections, which may be suggestive of C. perfringens bacteremia.
The 30-day mortality was 26.9%, nearly identical to that found
in a previous study by Fujita et al.5 That study included 18 cases of
C. perfringens bacteremia; the case population was elderly, and the
30-day mortality rate was 27%. The only medical characteristic
related to mortality was shock. Most of our patients received
adequate antimicrobial therapy initially, however the treatment
did not correlate to the prognosis. Patients with nosocomial
infections or poor health status, such as those with a high Charlson
WIC or stay in the ICU, had a higher mortality rate.
In our study, extreme age and multiple comorbidities, such as
renal insufﬁciency and malignancy, signiﬁcantly increased the risk
of acquiring C. perfringens bacteremia. The increased risk may be
due to the increased number of comorbid illnesses in elderly
people and perhaps more age-related colonization of Clostridium
species in the intestine.22 One study reported that hemodialysis
patients had an increased risk for developing Clostridiumbacteremia compared to the general population.22,25 Frequent
vascular access and the higher incidence of concurrent comorbid
illness in that population may increase the risk of clostridial
infections.25
Cancer and immunosuppression are consistently reported as
the main comorbidities in patients infected with C. perfringens.10,26
Similarly, 39 patients (41.9%) in our study had malignancies, and of
note, hepatocellular carcinoma and cholangiocarcinoma predomi-
nated. This differentiates our study from the previous study.26
Malignancy itself is a potential factor that can destroy the mucosal
barrier and thereby increase the potential for bloodstream
infections.14,27 Furthermore, the GI mucosal injury may be caused
by cytotoxic drugs, radiation, chemotherapy, or embolization.10
Besides invasive infections through the GI mucosa, any condition
that causes respiratory tract tunnel formation, lumen obstruction,
and swallowing difﬁculties may result in aspiration pneumonia of
the oropharyngeal or GI ﬂora.
Nosocomial C. perfringens bacteremia was not rare in our
patients (23/93, 24.7%) and caused a mortality rate of up to 60.9%.
Further, nosocomial infection was a signiﬁcant predictor of 30-day
mortality independent of other parameters. At the time of
bacteremia onset, patients with nosocomial C. perfringens bacter-
emia may have several underlying diseases and poor anaerobic
ﬂora coverage. Thus, the prognosis of this population is relatively
poor. More than a half of patients with community-acquired C.
perfringens bacteremia had IAI, and this ﬁnding should alert
physicians to give broad-spectrum coverage for anaerobes and
administer appropriate adjunctive therapies to destroy the
residential environments of C. perfringens.
The Pitt bacteremia score has been used to predict the mortality
of bacteremia more commonly than the APACHE II scoring system
and the Charlson WIC, because of its higher sensitivity and
speciﬁcity for bacteremia caused by certain bacterial strains,
including Staphylococcus aureus, extended-spectrum beta-lacta-
mase-producing E. coli, Pseudomonas aeruginosa, and Fusobacter-
ium nucleatum.21,27 In our study, the Pitt bacteremia score was not
an effective predictor for the prognosis of C. perfringens bacteremia.
Instead, the Charlson WIC was more effective for predicting the
C.-C. Yang et al. / International Journal of Infectious Diseases 17 (2013) e955–e960e960prognosis as it reﬂected the multiple comorbidities in our patient
population.
Compared to the 14% of clindamycin resistance (overall) for C.
perfringens isolates in Canada,22 the isolates in our study exhibited
a high in vitro susceptibility to penicillin, ampicillin/sulbactam,
piperacillin, metronidazole, and clindamycin (all >90%).
This study has several limitations. First, we only included
hospitalized patients and not outpatients referred from or
transferred to other hospitals. Patients with incomplete medical
records and those who were lost to follow-up after discharge were
also excluded. Second, the antibiotic regimens varied among
individual cases, hence it was difﬁcult to evaluate the efﬁcacy and
draw conclusions on the optimal therapeutic strategies for such a
critical infection.
In summary, C. perfringens bacteremia, although relatively
uncommon, is associated with a signiﬁcant disease burden,
especially intra-abdominal infections and pneumonia. Patients
with multiple comorbid illnesses, especially renal insufﬁciency
and malignancy, are at the highest risk for acquiring this type of
infection. Nosocomial bacteremia was a signiﬁcant mortality
predictor independent of other parameters of disease severity. It is
important that this critical infection is recognized earlier and that
appropriate antibiotic treatment with surgical debridement or
drainage is initiated as soon as possible.
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